Andrew Chantry - Concepedia

Author

Andrew Chantry

Also Known As

A Chantry, A. Chantry, A. D. Chantry, A.D. Chantry, ANDREW CHANTRY, Andrew Chantry, Andrew D Chantry, Andrew D. Chantry, Andrew Douglas Chantry, Andrew. D. Chantry

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of Sheffield Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital University College London Vrije Universiteit Brussel

About

Andrew Chantry is an author at University of Sheffield specializing in medicine, immunology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.1K
2	Health Sciences	5	5	774
3	Cell Biology	4	4	233
4	Cellular Therapies	2	2	253
5	Blood Transplantation	1	1	22

Andrew Chantry

Publications

Citations

H-Index

Page 1

	Year	Citations
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma D Heath, Andrew Chantry, Clive Buckle, Journal of Bone and Mineral Research	2008	240
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold, The Lancet Regenerative MedicineCell TherapyTransplantationMarrow TransplantationPlacebo-controlled Phase 3	2018	231
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐<i>κ</i>B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma Evangelos Terpos, Deborah J. Heath, Amin Rahemtulla, British Journal of Haematology SclerostinRelapsed Multiple MyelomaImmunologyPathologyOsteoporosis	2006	219
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo Andrew Chantry, Debby Heath, Aaron W. Mulivor, Journal of Bone and Mineral Research Breast Cancer MetastasesSclerostinBone ResorptionTumor MicroenvironmentBone Morphogenic Protein	2010	145
Guidelines for the use of imaging in the management of patients with myeloma Andrew Chantry, Majid Kazmi, Sally F. Barrington, British Journal of Haematology	2017	127
The Kinase Domain and Membrane Localization Determine Intracellular Interactions between Epidermal Growth Factor Receptors Andrew Chantry Journal of Biological Chemistry	1995	70
ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation Dan Zhang, Kim De Veirman, Rong Fan, Stem Cell Research & Therapy	2020	49
Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience Lewis Kass-Iliyya, John A. Snowden, Alice Thorpe, Journal of Neurology	2020	47
NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease Michelle A. Lawson, Julia Paton‐Hough, Holly Evans, PLoS ONE	2015	43

Page 1